Dr. Samia Mohammed serves as a Research Scientist at Ceramedix, Inc. An experienced molecular biologist specializing in sphingolipid signaling pathways, she leads assay development studies to advance Ceramedix’s anti-ceramide antibody programs toward IND.
Dr. Mohammed brings nearly 10 years of sphingolipid research experience from prestigious academic institutions. At Stony Brook Cancer Center, she served as a Postdoctoral Associate, where she investigated how sphingolipid signaling pathways modulate cardiotoxic effects of chemotherapy using various models. Her research involved elucidating the transcriptional regulation of key genes in the ceramide signaling pathway, analyzing sphingolipid levels in patient plasma samples, and assessing markers of chemotherapy-induced fibrosis and inflammation. During her graduate studies, she led projects to explore the role of low-dose chemotherapy in breast cancer metastasis and verify downstream targets of sphingomyelinase in breast cancer pathology. Her dedicated research efforts contributed to securing over $1M in NIH funding, including a 2-year graduate fellowship. Additionally, she was an invited speaker at the Stony Brook University Department of Medicine seminar series and authored a book chapter on sphingolipid signaling pathways.
Dr. Mohammed has been an author on peer-reviewed publications and holds a PhD in molecular and cellular biology from Stony Brook University, an MA in biochemistry from Hunter College, and a BA from Macaulay Honors College at City University of New York, graduating cum laude.